ANTI-OBESITY EFFECT OF PTEROSTILBENE
2012 Annual Report
1a.Objectives (from AD-416):
The objective of this research is to investigate the anti-obesity effect of pterostilbene, by determining if pterostilbene reduces fat accumulation in rats. A further objective is to elucidate the mechanism of action by studying the effects of pterostilbene on lipid metabolism pathways in adipose tissue, liver and skeletal muscle.
1b.Approach (from AD-416):
Pterostilbene will be synthesized, and incorporated in the feeds. The study will consist of 3 groups: (1) rats fed a high-fat diet, (2) rats fed a high-fat diet supplemented with pterostilbene (15 mg/kg body weight), and (3) rats fed a high-fat diet supplemented with pterostilbene (30 mg/kg body weight). Immunochemical studies will be performed at the end of the feeding and effects on molecular markers related to triacylglycerol metabolism will be analyzed. Analysis of pterostilbene in serum and tissues will also be performed to determine accumulation in tissues.
During this reporting period, animal feeding studies to determine the anti-obesity effect of pterostilbene was completed. Two doses of pterostilbene were used in the study: 15 and 30 mg/kg body weight; PT15 and PT30 group, respectively. Pterostilbene was shown to significantly reduce total adipose tissue mass (15.1% in PT15 group and 22.9% in PT30 group). Biochemical analyses showed pterostilbene inhibited the activities of key enzymes involved in lipid synthesis, in the liver and adipose tissue. Additionally, the PT30 dose was also shown to increase fatty acid oxidation in the liver. A USDA patent was filed for these new findings. Additional information regarding this patent can be found on the report for the in-house project, 6408-41000-008-00D, "CHEMISTRY OF NATURAL PRODUCTS FOR NUTRACEUTICAL USE, PEST MANAGEMENT AND CROP DEVELOPMENT"